⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL28503994 | 0.97 | RAB9A (0.38) | — | |
| SCHEMBL8325180 | 0.88 | RAB9A (0.34) | — | |
| Sulfuric Acid SCHEMBL28501743 | 0.86 | RAB9A (0.38) | — | |
| SCHEMBL12360476 | 0.83 | RAB9A (0.43) | — | |
| SCHEMBL22239356 | 0.82 | CYP1A2 (0.35) | — | |
| SCHEMBL12243171 | 0.80 | — | — | |
| Chloroacetic Acid SCHEMBL28506513 | 0.78 | TSHR (0.43) | — | |
| SCHEMBL22025526 | 0.78 | KMT2A (0.42) | — | |
| SCHEMBL44722 | 0.74 | RAB9A (0.36) | — | |
| SCHEMBL178300 | 0.74 | KMT2A (0.44) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Appears in 2148 patents — a generic fragment claimed broadly, so it's down-weighted as IP noise. Top by claim status then date:
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4305038-B1 | KRAS G12D INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2025-01-29 | — | — | EP | claimed |
| EP-4076418-A1 | SOS1 INHIBITORS | Mirati Therapeutics, Inc. (US) | 2022-10-26 | — | — | EP | claimed |
| CN-115135315-A | SOS1 inhibitors | 米拉蒂治疗股份有限公司 | 2022-09-30 | — | — | CN | claimed |
| US-10927097-B2 | Indole compound as inhibitor of necrosis | LG CHEM, LTD. (KR) | 2021-02-23 | — | — | US | claimed |
| CN-112142698-A | Method for degrading N-acetylglucosamine by novel sulfonyl-containing green ionic liquid to generate 3-acetamido-5-acetylfuran | 天津工业大学 | 2020-12-29 | — | — | CN | claimed |
| EP-3037418-B1 | INDOLE COMPOUND AS INHIBITOR OF NECROSIS | LG CHEMICAL LTD (KR) | 2019-10-02 | — | — | EP | claimed |
| CN-105636956-B | Indole compounds as inhibitors of cellular necrosis | 株式会社LG化学 | 2019-07-09 | — | — | CN | claimed |
| US-9724333-B2 | Pyrazole derivative | GREEN TECH CO., LTD. (JP) | 2017-08-08 | — | — | US | claimed |
| US-20160228412-A1 | NOVEL PYRAZOLE DERIVATIVE | GREEN TECH CO., LTD. (JP) | 2016-08-11 | — | — | US | claimed |
| US-20160200709-A1 | INDOLE COMPOUND AS INHIBITOR OF NECROSIS | LG LIFE SCIENCES LTD. (KR) | 2016-07-14 | — | — | US | claimed |
| US-20060089382-A1 | 7-[3-(4-acetylpiperazin-1-yl)propoxy]-3-cyano-6-methoxy-4-[4-(3-methoxyprop-1-ynyl)-2,3-methylenedioxyanilino]quinoline; potent anti-tumour activity; inhibition of MEK enzymes involved in the MAPK kinase pathway, inhibiting the non-receptor tyrosine-specific protein kinases | ASTRAZENECA AB (SE) | 2006-04-27 | — | — | US | claimed |
| US-20050282856-A1 | 3-Cyano-quinoline derivatives | ASTRAZENECA AB (SE) | 2005-12-22 | — | — | US | claimed |
| US-6967216-B2 | Amino substituted dibenzothiophene derivatives for the treatment of disorders mediated by NP Y5 receptor | ASTRAZENECA AB (SE) | 2005-11-22 | — | — | US | claimed |
| EP-1575943-A1 | 3-CYANO-QUINOLINE DERIVATIVES | AstraZeneca AB (SE) | 2005-09-21 | — | — | EP | claimed |
| EP-1521751-A1 | SUBSTITUTED 3-CYANOQUINOLINES AS MEK INHIBITORS | Astrazeneca AB (SE) | 2005-04-13 | — | — | EP | claimed |
| US-6846827-B1 | Pyrimidine derivatives | ASTRAZENECA AB (SE) | 2005-01-25 | — | — | US | claimed |
| EP-1226126-B1 | PYRIMIDINE DERIVATIVES | ASTRAZENECA AB (SE) | 2005-01-05 | — | — | EP | claimed |
| WO-2004041811-A1 | 3-CYANO-QUINOLINE DERIVATIVES | ASTRAZENECA AB (SE) | 2004-05-21 | — | — | WO | claimed |
| WO-2004005284-A1 | SUBSTITUTED 3-CYANOQUINOLINES AS MEK INHIBITORS | ASTRAZENECA AB (SE) | 2004-01-15 | — | — | WO | claimed |
| US-20030225097-A1 | Amino substituted dibenzothiophene derivatives for the treatment of disorders mediated by np y5 receptor | ASTRAZENECA AB (SE) | 2003-12-04 | — | — | US | claimed |